Pembrolizumab (pembro) monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC): Results after a minimum of 41 months of follow-up from KEYNOTE-427 cohort A

Autor: McDermott, D. F., Lee, J-L., Bjarnason, G. A., Larkin, J., Gafanov, R., Kochenderfer, M. D., Jensen, N. V., Donskov, F., Malik, J., Poprach, A., Tykodi, S. S., Alonso-Gordoa, T., Cho, D. C., Geertsen, P. F., Climent Duran, M. A., Di Simone, C., Liu, H., Burgents, J., Rodriguez-Lopez, K., Atkins, M. B.

Publikováno v: McDermott, D F, Lee, J-L, Bjarnason, G A, Larkin, J, Gafanov, R, Kochenderfer, M D, Jensen, N V, Donskov, F, Malik, J, Poprach, A, Tykodi, S S, Alonso-Gordoa, T, Cho, D C, Geertsen, P F, Climent Duran, M A, Di Simone, C, Liu, H, Burgents, J, Rodriguez-Lopez, K & Atkins, M B 2021, ' Pembrolizumab (pembro) monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC): Results after a minimum of 41 months of follow-up from KEYNOTE-427 cohort A ', Annals of Oncology, vol. 32, no. Suppl. 5, 666P, pp. S691-S692 . https://doi.org/10.1016/j.annonc.2021.08.062

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3062::fa77fe7a54818732b4b33019032a6fa2
https://portal.findresearcher.sdu.dk/da/publications/e7d6877e-1e6c-4db0-b3b7-b56ac5b3212c

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

582P Health-related quality of life (HRQoL) at final analysis of the GALAHAD study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and DNA repair defects (DRD)

Autor: Smith, M.R., Sandhu, S.K., George, D.J., Chi, K.N., Saad, F., Thiery-Vuillemin, A., Stahl, O., Olmos, D., Danila, D., Gafanov, R., Castro, E., Moon, H., Joshua, A.M., Mason, G.E., Espina, B.M., Liu, Y., Bevans, K.B., Lopez-Gitlitz, A., Francis, P., Fizazi, K.

Publikováno v: In Annals of Oncology September 2021 32 Supplement 5:S632-S633

662P Pembrolizumab (pembro) monotherapy as first-line therapy in advanced non–clear cell renal cell carcinoma (nccRCC): Results after a minimum of 34 months of follow-up from KEYNOTE-427 cohort B

Autor: Lee, J-L., McDermott, D.F., Ziobro, M., Suarez, C., Langiewicz, P., Matveev, V.B., Wiechno, P., Gafanov, R., Tomczak, P., Pouliot, F., Donskov, F., Alekseev, B.Y., Shin, S.J., Bjarnason, G.A., Castellano, D., Liu, H., Burgents, J., Rodriguez-Lopez, K., Atkins, M.B.

Publikováno v: In Annals of Oncology September 2021 32 Supplement 5:S687-S687

LBA4 IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC)

Autor: de Bono, J.S., Bracarda, S., Sternberg, C.N., Chi, K.N., Olmos, D., Sandhu, S., Massard, C., Matsubara, N., Alekseev, B., Gafanov, R., Parnis, F., Buchschacher, G.L., Jr., Corrales, L., Borre, M., Vasconcelos Alves, G., Garcia, J., Harle-Yge, M-L., Chen, G., Wongchenko, M.J., Sweeney, C.

Publikováno v: In Annals of Oncology September 2020 31 Supplement 4:S1153-S1154